ArticleDiscover oncology2025
Lesson from a metastatic male breast cancer case: CDK4/6 plus aromatase inhibitors could not exceed tamoxifen.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male breast cancer (MaBC) is a rare disease, and treatment approaches are often extrapolated from female breast cancer protocols. We present the case of a 55-year-old male diagnosed with estrogen receptor-positive metastatic breast cancer who exhibited primary resistance to first-line treatment with a combination of Palbociclib (CDK4/6 inhibitor) and Letrozole (aromatase inhibitor), despite the proven efficacy of this combination in female breast cancer. Surprisingly, upon switching to Tamoxifen, the patient showed rapid and significant clinical improvement documented as a good partial response on radiologic assessment. This case highlights the potential limitations of CDK4/6 inhibitors plus aromatase inhibitors in MaBC and suggests that Tamoxifen could remain a more reliable first-line endocrine therapy in males. It underscores the need for cautious extrapolation of female breast cancer treatment strategies to MaBC and emphasizes the adherence to classical approaches, such as tamoxifen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.